Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4208-4212

  Suzuki, Takayoshi ^a   Hisakawa, Shinya ^a   Itoh, Yukihiro ^a   Suzuki, Nobuaki ^a   Takahashi, Katsumasa ^a   Kawahata, Masatoshi ^b   Yamaguchi, Kentaro ^b   Nakagawa, Hidehiko ^a   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b Drug Research Department   (Japan)

Author keywords

Folate conjugate; Histone deacetylase inhibitor; Prodrug; Selective anticancer activity

Indexed keywords

ANTINEOPLASTIC AGENT; FOLATE RECEPTOR; HISTONE DEACETYLASE INHIBITOR; NCH 31; PRODRUG; THIOLATE HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

CARRIER PROTEINS; CELL LINE, TUMOR; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; PRODRUGS; RECEPTORS, CELL SURFACE; SULFHYDRYL COMPOUNDS;

EID: 34447093841     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.040     Document Type: Article

References (28)

1. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
2. Miller T.A. Expert Opin. Ther. Pat. 14 (2004) 791
3. Biel M., Wascholowski V., and Giannis A. Angew. Chem. Int. Ed. Engl. 44 (2005) 3186
4. Suzuki T., and Miyata N. Curr. Med. Chem. 13 (2006) 935
5. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3003
6. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruno T., and Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4592
7. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Clin. Cancer Res. 9 (2003) 3578
8. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. J. Clin. Oncol. 23 (2005) 3923
9. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. J. Clin. Oncol. 23 (2005) 3912
10. Antony A.C. Blood 79 (1992) 2807
11. Ross J.F., Chaudhuri P.K., and Ratnam M. Cancer 73 (1994) 2432
12. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., and Kamen B.A. Cancer Res. 52 (1992) 3396
13. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., and Kamen B.A. Cancer Res. 52 (1992) 6708
14. Leamon C.P., and Reddy J.A. Adv. Drug Deliv. Rev. 56 (2004) 1143
15. Canevari S., Mezzanzanica D., Menard S., Ferrini S., Moretta L., and Colnaghi M.I. Int. J. Cancer 7 (1992) 42
16. Yamaguchi T., Tsurumi H., Kotani T., Yamaoka N., Otsuji E., Kitamura K., and Takahashi T. Jpn. J. Cancer Res. 85 (1994) 167
17. Suzuki T., Kouketsu A., Matsuura A., Kohara A., Ninomiya S., Kohda K., and Miyata N. Bioorg. Med. Chem. Lett. 14 (2004) 3313
18. Suzuki T., Matsuura A., Kouketsu A., Nakagawa H., and Miyata N. Bioorg. Med. Chem. Lett. 15 (2005) 331
19. Suzuki T., Kouketsu A., Itoh Y., Hisakawa S., Maeda S., Yoshida M., Nakagawa H., and Miyata N. J. Med. Chem. 49 (2006) 4809
20. Suzuki T., Nagano Y., Kouketsu A., Matsuura A., Maruyama S., Kurotaki M., Nakagawa H., and Miyata N. J. Med. Chem. 48 (2005) 1019
21. Suzuki T., Hisakawa S., Itoh Y., Maruyama S., Kurotaki M., Nakagawa H., and Miyata N. Bioorg. Med. Chem. Lett. 17 (2007) 1558
22. Luo J., Smith M.D., Lantrip D.A., Wang S., and Fuchs P.L. J. Am. Chem. Soc. 119 (1997) 10004
23. 50 values are determined using a regression analysis of the concentration/inhibition data.
24. 2 for 72 h. Then, 10 μL of alamarBlue™ was added, and cells were incubated at 37 °C for 3 h. The fluorescence of the wells was measured on a fluorometric reader with excitation set at 530 nm and emission detection set at 590 nm, and the percentage of cell growth was calculated from the fluorescence readings.
25. Lee E.S., Na K., and Bae Y.H. J. Control. Release 91 (2003) 103
26. 5) were treated for 14 h with samples at the indicated concentrations in 10% FBS-supplemented DMEM then collected and extracted with SDS buffer. Protein concentrations of the lysates were determined using a Bradford protein assay kit (Bio-Rad Laboratories); equivalent amounts of proteins from each lysate were resolved in 15% SDS-polyacrylamide gel and then transferred onto nitrocellulose membranes (Bio-Rad Laboratories). After blocking for 30 min with Tris-buffered saline (TBS) containing 3% skim milk, the transblotted membrane was incubated overnight at 4 °C with hyperacetylated histone H4 antibody (Upstate Biotechnology) (1:2000 dilution) or β-actin antibody (Abcam) (1:1000 dilution) in TBS containing 3% skim milk. After probing with the primary antibody, the membrane was washed twice with water, then incubated with goat anti-rabbit or anti-mouse IgG-horseradish peroxidase conjugates (diluted 1:5000) for 2 h at room temperature, and further washed twice with water. The immunoblots were visualized by enhanced chemiluminescence.
27. Whittaker M., Floyd C.D., Brown P., and Gearing A.J.H. Chem. Rev. 99 (1999) 2735
28. Bell I.M. J. Med. Chem. 47 (2004) 1869